Compare PXLW & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PXLW | MURA |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1M | 36.0M |
| IPO Year | 2000 | N/A |
| Metric | PXLW | MURA |
|---|---|---|
| Price | $6.16 | $2.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $14.33 | $6.00 |
| AVG Volume (30 Days) | 90.3K | ★ 224.8K |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,205,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.67 | $0.95 |
| 52 Week High | $15.42 | $4.74 |
| Indicator | PXLW | MURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 40.39 |
| Support Level | $5.75 | $2.06 |
| Resistance Level | $6.80 | $2.10 |
| Average True Range (ATR) | 0.39 | 0.01 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 34.12 | 25.00 |
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.